Novel anti-fibrotic therapy for cardiovascular disease
- Research Opportunity
- Honours, Master of Biomedical Science
- Project Status
- Medicine and Radiology
- St Vincent's Hospital
|Dr Andrew Kompaemail@example.com||9288 3244||Personal web page|
The pathophysiologic progression to heart failure is a complex process. Initial insults such a myocardial infarction or chronic hypertension, trigger the activation of neuro-hormonal systems in the body in an attempt to restore cardiac function. However, long-term activation of this system becomes maladaptive by causing cellular and molecular changes in the heart which leads to cardiac remodeling and eventually leading to heart failure. Cardiac fibrosis is one of the key cardiac remodeling processes. Thus, anti-fibrotic therapy could be of particular important in the management of heart failure.
We have recently validated a novel pathway that is particularly important for cardiac fibrosis. In collaboration with Monash Institute of Pharmaceutical Sciences (MIPS), we have developed novel compounds that inhibit the fibrotic pathway with anti-fibrotic activity.
This project will provide opportunity for the student to take part in this discovery and development process.
The project will initially focus on cell-based assays to characterize the effects of those novel compounds including signaling pathways involved. This will validate the mode of action of the compounds and the role of the signaling molecule play in cardiovascular diseases.
From this project the candidate will acquire skills and experience in aseptic cell culture technique, the ability to perform various cell based assays, RNA extractions and real time PCR, Western blot analysis and knowledge of cardiac pharmacology.
This research project is available to Honours, Master of Biomedical Science students to join as part of their thesis.
Please contact the supervisor to discuss your options.
School Research Themes
For further information about this research, please contact a supervisor.